tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Michelle Gilson, 56 are a BUY (94.92%), 3 are a HOLD (5.08%).
Analyst Michelle Gilson, carries an average stock price target met ratio of 47.27% that have a potential upside of 33.42% achieved within 214 days. Previously, Michelle Gilson worked at CANACCORD.
Michelle Gilson’s has documented 109 price targets and ratings displayed on 12 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on VIR, Vir Biotechnology at 08-Jan-2025.
Analyst best performing recommendations are on SRPT (SAREPTA THERAPEUTICS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 9/14/2016. The price target of $60 was fulfilled within 8 days with a profit of $27.55 (84.9%) receiving and performance score of 106.12.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$260
$65.7 (33.81%)
$254
10 days ago
(19-Aug-2025)
21/25 (84%)
$65.38 (33.59%)
155
Buy
$243
$48.7 (25.06%)
$207
1 months 18 days ago
(11-Jul-2025)
10/12 (83.33%)
$68.04 (38.89%)
779
Buy
$250
$55.7 (28.67%)
$250
1 months 26 days ago
(03-Jul-2025)
20/22 (90.91%)
$75.82 (43.53%)
278
Buy
$224
$29.7 (15.29%)
$180
2 months 16 days ago
(13-Jun-2025)
6/11 (54.55%)
$53.2 (31.15%)
548
Buy
$216
$21.7 (11.17%)
$201
2 months 20 days ago
(09-Jun-2025)
12/14 (85.71%)
$42.85 (24.75%)
273
What Year was the first public recommendation made by Michelle Gilson?
